Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 31, 2006

Study Completion Date

August 31, 2008

Conditions
HypogonadismErectile Dysfunction
Interventions
DRUG

Fispemifene (once daily for 8 weeks)

Trial Locations (14)

14221

Center for Urologic Research of WNY, LLC, Williamsville

28025

NorthEast Urology research, Concord

28207

Metrolina Urology Clinic, Charlotte

32779

Genesis Research International, Longwood

33407

Radiant Research, West Palm Beach

34471

Renstar Medical Research, Ocala

35209

Radiant Research, Birmingham

37209

Urology Associates, P.C., Nashville

71106

Regional Urology, Shreveport

71913

HealthStar Research, Hot Springs

78229

Radiant Research, San Antonio

85741

Genova Clinical Research, Tucson

89144

Office of Stephen Miller, Las Vegas

08690

Hamilton Urology, Hamilton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Hormos Medical

INDUSTRY

lead

QuatRx Pharmaceuticals Company

INDUSTRY

NCT00415571 - Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors | Biotech Hunter | Biotech Hunter